News Updates
More Articles
- The Pitfalls and Promise of Cell and Gene Therapy Development: A Time for Concerted Action
- “Not Just Checking a Box”: A Call to Rethink Patient Involvement in the EU
- From Cells to Animals and Back Again: The Shifting Landscape of Cancer Efficacy and Safety Models
- Addressing Inequity: Embedding Inclusion and Diversity in UK Clinical Trials
- The Next AI Revolution: Computer System Validation
Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
In response to collective calls to action, Patient Focused Medicines Development (PFMD) built upon previous collaborative work with the National Health Council (NHC) and the Workgroup of European Cancer Patient Advocacy Networks (WECAN) to outline practical solutions that support PE partners in navigating remuneration and in effectively applying fair market value (FMV) rates.